Abstract
2113 Initial safety survey report from early post-marketing phase vigilance (EPPV) on TAS-102 for metastatic colorectal cancer (mCRC)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
